Colistin for lung infection: An update

Journal of Intensive Care

Volumn 3, Issue 1, 2015, Pages

  Gurjar, Mohan ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Colistin; Critically ill; Lung infection; Pneumonia; Ventilator associated pneumonia

Indexed keywords

COLISTIMETHATE; COLISTIN; CREATININE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; CHEMICAL STRUCTURE; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; INCIDENCE; KIDNEY FAILURE; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; STRESS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84979197352     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/s40560-015-0072-9     Document Type: Review

References (79)

1. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009, 22:535-43. 10.1097/QCO.0b013e328332e672, 19797945.
2. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601. 10.1016/S1473-3099(06)70580-1, 16931410.
3. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008, 24:377-91. 10.1016/j.ccc.2007.12.003, 18361952.
4. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010, 53:1898-916. 10.1021/jm900999h, 19874036.
5. Koyama Y, Kurosawa A, Tsuchiya A, Takemuta K. A new antibiotic 'colistin' produced by spore-forming soil bacteria. J Antibiot (Tokyo) 1950, 3:457-8.
6. Balaji V, Jeremiah SS, Baliga PR. Polymyxins: antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol 2011, 29:230-42. 10.4103/0255-0857.83905, 21860102.
7. Gupta S, Govil D, Kakar PN, Prakash O, Arora D, Das S, et al. Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med 2009, 13:49-53. 10.4103/0972-5229.56048, 19881183.
8. Campos MA, Vargas MA, Regueiro V, Llompart CM, Albertí S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004, 72:7107-14. 10.1128/IAI.72.12.7107-7114.2004, 15557634.
9. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001, 39:183-90. 10.1128/JCM.39.1.183-190.2001, 11136768.
10. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii . Antimicrob Agents Chemother 2006, 50:2946-50. 10.1128/AAC.00103-06, 16940086.
11. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011, 1:30. 10.1186/2110-5820-1-30, 21906382.
12. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008, 30:143-51. 10.1016/j.clinthera.2008.01.015, 18343250.
13. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K, Tofas P, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010, 22:175-8. 10.1179/joc.2010.22.3.175, 20566422.
14. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009, 53:3430-6. 10.1128/AAC.01361-08, 19433570.
15. Karnik ND, Sridharan K, Jadhav SP, Kadam PP, Naidu RK, Namjoshi RD, et al. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. Eur J Clin Pharmacol 2013, 69:1429-36. 10.1007/s00228-013-1493-9, 23508665.
16. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010, 54:3783-9. 10.1128/AAC.00903-09, 20585118.
17. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010, 138:1333-9. 10.1378/chest.10-0463, 20558557.
18. Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2013, 57:668-71. 10.1128/AAC.00985-12, 23147733.
19. Honoré PM, Jacobs R, Joannes-Boyau O, Lochy S, Boer W, De Waele E, et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 2014, 37(4):291-5. 10.1159/000363495, 25096804.
20. Antoniu SA, Cojocaru I. Inhaled colistin for lower respiratory tract infections. Expert Opin Drug Deliv 2012, 9:333-42. 10.1517/17425247.2012.660480, 22332963.
21. Michalopoulos A, Papadakis E. Inhaled anti-infective agents: emphasis on colistin. Infection 2010, 38:81-8. 10.1007/s15010-009-9148-6, 20191398.
22. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006, 57:306-11. 10.1093/jac/dki461, 16396919.
23. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010, 36:1147-55. 10.1007/s00134-010-1879-4, 20397007.
24. Colomycin package insert information. Colomycin 1,000,000 IU vial-colistin sulphomethate sodium 1998, Pharmax Ltd, Bexley, Bexley.
25. Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008, 29:277-96. 10.1016/j.ccm.2008.02.003, 18440437.
26. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008, 14:816-27. 10.1111/j.1469-0691.2008.02061.x, 18844682.
27. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006, 57:573-6. 10.1093/jac/dki477, 16431863.
28. Safarika A, Galani I, Pistiki A, Giamarellos-Bourboulis EJ. Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis. 2014 Sep 6. [Epub ahead of print].
29. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii . Antimicrob Agents Chemother 2008, 52:333-6. 10.1128/AAC.00689-07, 17967915.
30. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?. Antimicrob Agents Chemother 2009, 53:2133-5. 10.1128/AAC.01271-08, 19258266.
31. Leu HS, Ye JJ, Lee MH, Su LH, Huang PY, Wu TL, Huang CT. Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii. J Microbiol Immunol Infect. 2013 Jul 5. doi:pii: S1684-1182(13)00086-8. 10.1016/j.jmii.2013.05.007. [Epub ahead of print]..
32. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27. 10.1186/cc3995, 16507149.
33. Balkan II, Dogan M, Durdu B, Batirel A, Hakyemez IN, Cetin B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014, 46(10):678-85. 10.3109/00365548.2014.926021, 25073536.
34. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012, 54:1720-6. 10.1093/cid/cis286, 22423120.
35. Dewan A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration. Indian J Crit Care Med 2014, 18(7):427-30. 10.4103/0972-5229.136070, 25097354.
36. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970, 72:857-68. 10.7326/0003-4819-72-6-857, 5448745.
37. Perkins RL. Apnea with intramuscular colistin therapy. JAMA 1964, 190:421-4. 10.1001/jama.1964.03070180019004, 14197992.
38. de Gouw NE, Crul JF, Vandermeersch E, Mulier JP, van Egmond J, Van Aken H. Interaction of antibiotics on pipecuronium-induced neuromuscular blockade. J Clin Anesth 1993, 5:212-5. 10.1016/0952-8180(93)90017-9, 8391282.
39. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36(9):1111-8. 10.1086/374337, 12715304.
40. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa . Clin Infect Dis 2003, 37(11):e154-60. 10.1086/379611, 14614688.
41. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003, 7(5):R78-83. 10.1186/cc2358, 12974973.
42. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006, 25(9):596-9. 10.1007/s10096-006-0191-2, 16955249.
43. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii . J Infect 2006, 53(4):274-8. 10.1016/j.jinf.2005.11.019, 16442632.
44. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007, 33(7):1162-7. 10.1007/s00134-007-0675-2, 17530220.
45. Rios FG, Luna CM, Maskin B, Saenz Valiente A, Lloria M, Gando S, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007, 30(2):307-13. 10.1183/09031936.00156906, 17504791.
46. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008, 56(6):432-6. 10.1016/j.jinf.2008.04.002, 18501431.
47. Song JY, Lee J, Heo JY, Noh JY, Kim WJ, Cheong HJ, et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii . Int J Antimicrob Agents 2008, 32(3):281-4. 10.1016/j.ijantimicag.2008.04.013, 18650070.
48. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg Infect (Larchmt) 2008, 9(2):153-60. 10.1089/sur.2007.004.
49. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008, 61(2):417-20. 10.1093/jac/dkm509, 18174197.
50. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008, 102(3):407-12. 10.1016/j.rmed.2007.10.011, 18060758.
51. Taşbakan MS, Pullukçu H, Ekren PK, Oz AT, Midilli M, Aydemir S, et al. Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii . Mikrobiyol Bul 2009, 43(1):61-70. 19334381.
52. Jang HJ, Kim MN, Lee K, Hong SB, Lim CM, Koh Y. The comparative efficacy of colistin monotherapy and combination therapy based on in vitro antimicrobial synergy in ventilator-associated pneumonia caused by multi-drug resistant Acinetobacter baumannii . Tuberc Respir Dis; 2009, 67(3):212-20. 10.4046/trd.2009.67.3.212.
53. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010, 51(11):1238-44. 10.1086/657242, 20973727.
54. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010, 16(8):1230-6. 10.1111/j.1469-0691.2009.03040.x, 19732088.
55. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010, 65(12):2645-9. 10.1093/jac/dkq360, 20876621.
56. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010, 43(4):323-31. 10.1016/S1684-1182(10)60050-3, 20688293.
57. Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V, et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010, 169(7):867-74. 10.1007/s00431-009-1137-3, 20119725.
58. Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, et al. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatr Pulmonol 2011, 46(1):60-6. 10.1002/ppul.21324, 20812247.
59. Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S. Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva 2011, 35(4):226-31. 10.1016/j.medin.2011.01.013, 21396739.
60. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa . BMC Infect Dis 2011, 11:317. 10.1186/1471-2334-11-317, 22085766.
61. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012, 117(6):1335-47. 10.1097/ALN.0b013e31827515de, 23132092.
62. Simsek F, Gedik H, Yildirmak MT, Iris NE, Türkmen A, Ersoy A, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy?. Indian J Med Microbiol 2012, 30(4):448-52. 10.4103/0255-0857.103767, 23183471.
63. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?. J Infect Chemother 2012, 18(6):872-7. 10.1007/s10156-012-0430-7, 22644081.
64. Zalts R, Neuberger A, Hussein K, Raz-Pasteur A, Geffen Y, Mashiach T, Finkelstein R. Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam. Am J Ther. 2013 Nov 20. [Epub ahead of print].
65. Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 2013, 144(6):1768-75. 10.1378/chest.13-1018, 23989805.
66. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013, 141(6):1214-22. 10.1017/S095026881200194X, 22954403.
67. Doshi NM, Cook CH, Mount KL, Stawicki SP, Frazee EN, Personett HA, et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol 2013, 13(1):45. 10.1186/1471-2253-13-45, 24274315.
68. Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, Espejo-Gutiérrez De Tena E, Artero-González ML, Corcia-Palomo Y, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 2013, 59(3):225-31. 10.1159/000356004, 24356297.
69. Kalin G, Alp E, Akin A, Coskun R, Doganay M. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 2014, 42(1):37-42. 10.1007/s15010-013-0495-y, 23828559.
70. Hsieh TC, Chen FL, Ou TY, Jean SS, Lee WS. Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization. J Microbiol Immunol Infect. 2014 Oct 31. pii: S1684-1182(14)00178-9. doi:10.1016/j.jmii.2014.08.009. [Epub ahead of print].
71. Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 2014, 43(4):378-82. 10.1016/j.ijantimicag.2014.01.016, 24613422.
72. Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 2014, 14:102. 10.1186/1471-2334-14-102, 24564226.
73. Soubirou JF, Gault N, Alfaiate T, Lolom I, Tubach F, Andremont A, et al. Ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii . Scand J Infect Dis 2014, 46(3):215-20. 10.3109/00365548.2013.871644, 24447250.
74. Choi HK, Kim YK, Kim HY, Uh Y. Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii . Yonsei Med J 2014, 55(1):118-25. 10.3349/ymj.2014.55.1.118, 24339296.
75. Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother 2014, 58(2):851-8. 10.1128/AAC.00871-13, 24277037.
76. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012, 54:670-80. 10.1093/cid/cir934, 22322268.
77. Gu WJ, Wang F, Tang L, Bakker J, Liu JC. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. Int J Antimicrob Agents. 2014 Aug 10. pii: S0924-8579(14)00235-0. doi:10.1016/j.ijantimicag.2014.07.004. [Epub ahead of print].
78. Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med. 2014 Dec 9. [Epub ahead of print].
79. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2014 Oct 21. pii: S1473-3099(14)70850-3. doi: 10.1016/S1473-3099(14)70850-3. [Epub ahead of print].